



# SARS-CoV-2 Modes of Transmission and Related IPC Measures

Tuesday, April 28, 2020 |

John Conly, University of Calgary and Alberta Health Services, Calgary, Canada



# Territorial Acknowledgement



ii' taa'poh'to'p

Source: <https://www.ucalgary.ca/indigenous>

# Dr. John Conly

- Medical Director for W21C at the O'Brien Institute for Public Health, and Co-Director for the Snyder Institute for Chronic Diseases at the University of Calgary
- Professor in the Departments of Medicine / Microbiology, Immunology & Infectious Diseases and Pathology & Laboratory Medicine at the Cumming School of Medicine, University of Calgary
- Medical Director for IPC, Alberta Health Services – Calgary and Area
- Appointed as a member of the Order of Canada in 2018 for pioneering contributions in IPC, antimicrobial resistance and healthcare innovations.



# Faculty/Presenter Disclosure/Acknowledgements

- **Financial disclosure affiliations**

- **Honoraria:** None
- **Speakers' Bureaux, advisory boards:** Received funding to attend a meeting on HAI from the CDC and bioMerieux
- **Grants/Clinical Trials:** Local PI for the STRIVE *S. aureus* vaccine trial spinal surgery (Pfizer) and holds grants from CIHR, AI-HS, PHAC, AH, AHS, EDT.
- **Patents, royalties:** None
- **Investments in health organizations:** None
- **Other influential affiliations:** Member of committees with PHAC, WHO and CIHR

- **Acknowledgements**

- Dr J Gill/ G van Marle for permission to use some of their slides

# Sorting the Message

- Mainstream media and social media in **total overdrive**
- First major pandemic in the “modern age” of **instant social messaging**
- Lots of “papers” now published online before even reviewed
- “Science” may be correct but may jump to premature or incorrect conclusions or be incomprehensible; some will never be published
- Even in top quality peer-viewed journals the articles may be premature / over interpreted / incomplete and without necessary limitations
- Many letters and short reports
- Authors, reviewers and journals are under immense pressure to be fast and first in publishing
- **Be careful and use your critical appraisal skills and common sense**

# Basic Viral Facts

- The SARS-CoV-2 causes COVID-19 infection.
- Single strand RNA virus in coronavirus family named from morphology
- It is a respiratory virus (contact droplet **not** airborne transmission)
- Only a few coronaviruses cause human illness (mostly **respiratory** such as colds but also serious respiratory infections SARS and MERS)
- Uses human ACE 2 receptor( Angiotensin converting enzyme 2)
- **VERY high affinity** for receptor vs. SARS (i.e. readily latches onto respiratory cells ? few viruses needed for infection)

# SARS -CoV-2

- SARS-CoV-2 likely originated from Asian bats into intermediary animal host ( the pangolin ) and then to humans
- Virus not mutating significantly. So vaccine more possible but virus less likely to “flame out” or become less pathogenic
- Variation is, however, enough for phylogenetic studies  
<https://nextstrain.org/narratives/ncov/sit-rep/2020-03-27>
- IgG and IgM Antibody tests are close: Will be very useful for determining natural history and possible health care staffing
- No one is immune

# Natural History in Humans

- Proportion of asymptomatic infections unknown and critical for understanding possible transmission and HCW immunity.
- Estimates range 0-6% but models higher
- Incubation period after exposure likely 2-14 days (median ~5 days)
- 97.5% develop symptoms within 11 days
- Of those diagnosed
  - 80% have self-limited mainly respiratory illness probably of ~ 14 days duration
  - 15% have more severe illness requiring medical care +/- hospitalization
  - 5% go to intensive care +/- ventilation
- Risk in hospitalized is mainly respiratory then multi organ failure requiring ventilation and high risk of death ~ 70% ventilated patients
- Progression risk and rate down pathway below is unclear



# Diagnostic Clinical Challenges

## Influenza-like-illness (ILI)

- **New or changed cough**

AND one or more of the following:

- **Fever** (or history of fever in the last 24 hours)
- **Muscle aches**
- **Severe exhaustion/weakness**
- Sore throat
- Joint pain

## COVID-19


- **Fever** (98%)
- **Cough** (76%)
- **Myalgia or fatigue** (44%)
- Sore throat
- Sputum production (28%)
- Headache (8%)
- Mild Diarrhea (? 3%)
- Hemoptysis (5%)
- Additional symptoms – skin lesions, strokes

# COVID-19 and SARS-CoV-2

## Infection Prevention and Control



# Transmission Routes



# Transmission Routes

- Droplet and airborne routes create most debate
- Continuum of droplet and airborne routes an important concept
- Particles of a variety of sizes are expelled from the human airway during coughing, sneezing, talking and medical procedures
- Size of these particles and the distance propelled is complex
  - particle sizes variable
  - distance they will be propelled is dependent on the force generated by the individual or the procedure
  - particles may or may not contain the infectious agent
  - infectious agent may or may not be viable
  - concentration of particles affected by many factors: the relative humidity, evaporation level, settling velocity, direction of air flow, the number of air changes per hour, temperature, crowding and other environmental factors
- Airborne may be obligate or preferential or opportunistic and refers to particles that stay aloft for minutes or hours (less than 5-10  $\mu\text{m}$  in diameter) and can be carried by air currents over a measurable distance
- Droplet spread refers to large droplets (  $>5\text{-}10\mu\text{m}$ ) that fall within 1 metre

# Exposure, Transmission and Invasive Infection

- Exposure to microorganisms
- Not all exposures lead to transmission and invasive infection.
- Exposure occurs when a host comes into contact with an infected source or contaminated environment (e.g., inanimate/animate object or particles in the air)
- Probability of transmission followed by invasive infection → many factors
  - host susceptibility
  - presence of host receptors
  - receptivity of host receptors
  - inoculum
  - viability
  - virulence
  - effectiveness of the hierarchy of controls

# SARS-CoV-1/ MERS-CoV Findings Relevant to IPC

- **Droplet and contact** – multiple studies demonstrated **compliance with gloves, gowns and medical masks or N95s** were adequate to prevent transmission for SARS
- **Major risks** exposure of eye and mucous membranes to **respiratory secretions and AGMPs**, ie intubation (**opportunistic airborne**); no association with contact with urine/stool
- **HCW spread** - associated with **inconsistent or improper PPE use** for SARS/MERS-CoV outbreaks; **Infections in HCWs: 22% and 25%** for SARS and MERS, respectively
- **Risk factors for nosocomial spread** of MERS-CoV in two large outbreaks in Saudi Arabia and South Korea found ER/Ward **overcrowding and sub-optimal control of visitors** were major factors
- **Transmission** of MERS-CoV **was not documented** in one investigation of mostly **asymptomatic** and **pauci-symptomatic** cases and their household contacts
- **Asymptomatic cases reported but uncommon** – one study of MERS cases found 80% of “asymptomatic” persons actually had symptoms on close questioning

Seto WH et al Lancet 2003; Raboud J et al Plos One 2010; Jefferson et al Cochrane Rev 2011; Oboho IK et al NEJM 2015; Kim SW CID 2017; Cheng VC et al Antiviral Res 2013; Van Kerkhove MD et al Sci Rep. 2019.

# SARS-CoV-2 Detection

## Patient specimens

- **BAL** samples (Zhu NEJM) + viral isolation
- **Nasopharyngeal/oropharyngeal** (NP/OP) swabs
  - multiple reports of detection of 2019-nCoV RNA in NP/OP swabs; sensitivity varies 71-100% and depends on operator, timing and site of specimen; specificity near 100%
  - shedding over time varies but recent studies elucidating
  - viable virus does not correlate well with RT-PCR depending on time
- **Serum**
  - Chan (Lancet 2020) also showed + RT-PCR of serum in one patient
- **Stool**
  - Investigators in Shenzhen and Washington State have detected 2019-nCoV RNA in the stool of infected patients (Holshue NEJM 2020)




Table I  
Persistence of coronaviruses on different types of inanimate surfaces


Type of surface	Virus	Strain / isolate	Inoculum (viral titer)	Temperature	Persistence	Reference	
Steel	MERS-CoV	Isolate HCoV-EMC/2012	10 <sup>5</sup>	20°C	48 h	[21]	
				30°C	8–24 h		
	TGEV	Unknown	10 <sup>6</sup>	4°C	≥ 28 d	[22]	
				20°C	3–28 d		
	MHV	Unknown	10 <sup>6</sup>	40°C	4–96 h	[22]	
				4°C	≥ 28 d		
20°C				4–28 d			
Aluminium	HCoV	Strain 229E	10 <sup>3</sup>	40°C	4–96 h	[23]	
				21°C	5 d		
	HCoV	Strains 229E and OC43	5 x 10 <sup>3</sup>	21°C	2–8 h	[24]	
				RT	5 d		
	Metal	SARS-CoV	Strain P9	10 <sup>5</sup>	RT	4 d	[25]
					RT	4–5 d	
Wood	SARS-CoV	Strain P9	10 <sup>5</sup>	RT	24 h	[26]	
				RT	3 h		
Paper	SARS-CoV	Strain P9	10 <sup>5</sup>	RT	< 5 min	[25]	
				RT	4 d		
	SARS-CoV	Strain GVU6109	10 <sup>6</sup>	RT	5 d	[23]	
				RT	6–9 d		
	Glass	SARS-CoV	Strain P9	10 <sup>5</sup>	RT	2–6 d	[28]
					RT	5 d	
Plastic	HCoV	Strain 229E	10 <sup>3</sup>	21°C	5 d	[23]	
				22°-25°C	≤ 5 d		
	SARS-CoV	Strain HKU39849	10 <sup>5</sup>	20°C	48 h	[21]	
				30°C	8–24 h		
	PVC	SARS-CoV	Strain P9	10 <sup>5</sup>	RT	4 d	[25]
					RT	6–9 d	
Silicon rubber	SARS-CoV	Strain FFM1	10 <sup>7</sup>	RT	2–6 d	[28]	
				RT	5 d		
Surgical glove (latex)	HCoV	Strain 229E	10 <sup>3</sup>	21°C	5 d	[23]	
				21°C	5 d		
Disposable gown	HCoV	Strains 229E and OC43	5 x 10 <sup>3</sup>	21°C	≤ 8 h	[24]	
				RT	2 d		
Ceramic	SARS-CoV	Strain GVU6109	10 <sup>6</sup>	RT	24 h	[26]	
					10 <sup>5</sup>		1 h
	HCoV	Strain 229E	10 <sup>3</sup>	21°C	5 d	[23]	
					10 <sup>4</sup>		5 d
	Teflon	HCoV	Strain 229E	10 <sup>3</sup>	21°C	5 d	[23]
					21°C	5 d	

MERS = Middle East Respiratory Syndrome; HCoV = human coronavirus; TGEV = transmissible gastroenteritis virus; MHV = mouse hepatitis virus; SARS = Severe Acute Respiratory Syndrome; RT = room temperature.




# Survival SARS-CoV-2





- Virus was readily isolated during the first week of symptoms from a considerable fraction of samples (16.66% in swabs, 83.33% in sputum samples)
- No isolates of virus obtained from samples taken after day 8 in spite of ongoing high viral loads by RT-PCR

# How SARS-CoV-2 spread compares to other viruses



**Basic reproductive number ( $R_0$ )**  
the average number of individuals infected by a case over the infectious period, in a fully susceptible population.  
**Most major studies suggest it is falling into range of 2.20 -2.68**  
**Korea and Italy of 2.60 (based on initial case growth)**

[Li Q et al N Engl J Med.](#) 2020 Mar 26;382(13):1199-1207; Wu JT [Lancet.](#) 2020 Feb 29;395(10225):689-697

Zhynag Z et al. [Int J Infect Dis.](#) 2020 Apr 22. pii: S1201-9712(20)30259-9.

# Mode Transmission SARS-CoV-2

- Droplet - contact considered predominant route
  - Consistent with SARS-CoV-1, MERS-CoV
  - Consistent with  $R_0$  of other droplet-contact respiratory viruses
- WHO-China Joint Mission on COVID-19 in China with 75,465 cases supported person-to-person droplet and fomite transmission
  - 78-85% of the investigated infection clusters occurred within families, with an intra-household 2<sup>o</sup> attack rate of 3-10%, not consistent with airborne transmission

# Reports against/for Airborne Transmission for CoVs

- 41 HCW exposure over 10 minutes within 2 meters to a COVID-19 patient during multiple AGMPs, 85% surgical masks and no transmission events
- COVID-19 + who was nursed in an open cubicle of a general ward before the diagnosis was made and 76 tests 52 contacts, some without PPE and no transmissions
- No evidence of COVID-19 transmission to passengers seated around a COVID+ passenger long flight
- No transmission events in 5544 continuous person hours HCW exposure to 132 inpatient COVID+ pts using medical masks as part of PPE routine care
- Amoy Garden outbreak Sars-CoV-1 > 300 residents possible aerosol event vs rats
- Report of a bus transmission 4.5 meters distance in Chinese report (translated)
- Outbreak in air-conditioned (AC) restaurant China with 10 persons with 1 meter distance between tables along flow of air from the AC
- Experimental study with 3-jet Collison nebulizer creating aerosol of viable SARS-CoV-2
- Systematic review of droplet dispersion but mainly modelling studies; no clinical settings or epidemiologic data

References:; Ng K et al Ann Int Med.16 Mar 2020; Wong SC-Y. J Hosp Inf 2020; :Schwartz K et al. CMAJ 24 March 2020; Conly J Unpublished

References: Yu IT et al [N Engl J Med.](#) 2004 Apr 22;350(17):1731-9; Luo Y et al. Pract Prev Med. 2020-03-05. Lu J et al. MMWR 26:7 July 2020; Van Doremalen N et al. N Engl J Med.2020 Apr 16;382(16):1564-1567; Bahl P et al. JID 2020;XX:1–8

# Reports against/for Airborne Transmission for CoVs


- SARS-CoV-2 (RT-PCR) in 1/13 (7.7%) environmental samples but 0/8 air samples collected 10 cm from the patient's chin in Hong Kong
- SARS-CoV-2 (RT-PCR) in 17/22 (77%) environmental samples but 0/5 air sample sites including beside the patient collected in Singapore
- None/10 air samples for SARS-CoV-2 (RT-PCR) with samplers with fresh DMEM 2 to 5 m away from the patient (severely ill)
- SARS-CoV-2 (RT-PCR) in 20/37 air samples at 1-113 copies/m<sup>3</sup> highest ICU – multiple areas hospital
- SARS-CoV-2 (RT-PCR) in 126/163 samples (77.3%) collected in this study, 0 to 1.75 copies/μL and air samples 2.86 copies/L including outside pt rooms; no viable virus cultivated in any of the 163 samples
- SARS-CoV-2 (RT-PCR) high touch surface contamination was shown in 10/15 (66.7%) rooms 1840 to 3380 RNA copies per m<sup>3</sup> ; viability not done

# Transmission Risks of SARS-CoV-2

- Prospective cohort study of 4,950 persons who had a close contact with confirmed COVID-2019 patients (n=129;2.6% [6.2% asymptomatic/38% mild/51.9% moderate/3.9% severe])
- RT- PCR q2 days; daily temp and symptom check
- Uni- and multivariable regression analysis (SAS) were performed for risk factors for developing COVID-19
- Age (1.8-4.2% 0-17 to > 60 yrs); household and multiplicity of contacts (10.2-13%) highest risk whereas public transport and HCW lowest (1.0 and 0.1%) and severity were (0.33 % asymptomatic/3.3% mild/5.6% moderate/6.2% severe]) and sputum production and fever all significant risk factors in MV analysis
- RT-PCR sensitivity **71.9%**; 93.2%; 96.9% **100%** at **1,2 ,3 and 6 tests**



# Building upon key existing WHO guidance



## Infection prevention and control during health care for probable or confirmed cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection

Interim guidance  
Updated October 2019

[WHO/MERS/IPC/15.1 Rev 1](#)



[https://apps.who.int/iris/bitstream/handle/10665/174652/WHO\\_MERS\\_IPC\\_15.1\\_eng.pdf;jsessionid=718B13F93CBB3B2DD7CCAA2623321BDF?sequence=1](https://apps.who.int/iris/bitstream/handle/10665/174652/WHO_MERS_IPC_15.1_eng.pdf;jsessionid=718B13F93CBB3B2DD7CCAA2623321BDF?sequence=1)

[https://www.who.int/csr/bioriskreduction/infection\\_control/publication/en/](https://www.who.int/csr/bioriskreduction/infection_control/publication/en/)



# 2019 n-CoV: WHO guidance

## Home care for patients with suspected novel coronavirus (nCoV) infection presenting with mild symptoms and management of contacts

Interim guidance  
20 January 2020



[https://www.who.int/publications-detail/home-care-for-patients-with-suspected-novel-coronavirus-\(ncov\)-infection-presenting-with-mild-symptoms-and-management-of-contacts](https://www.who.int/publications-detail/home-care-for-patients-with-suspected-novel-coronavirus-(ncov)-infection-presenting-with-mild-symptoms-and-management-of-contacts)

[https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-\(ncov\)-infection-is-suspected-20200125](https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-(ncov)-infection-is-suspected-20200125)

## Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected

Interim guidance  
25 January 2020



## Infection prevention and control during health care when COVID-19 is suspected

Interim guidance  
19 March 2020



[https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-\(ncov\)-infection-is-suspected-20200125](https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-(ncov)-infection-is-suspected-20200125)

# Principles of IPC Strategies associated with Health Care for Suspected COVID-19

1. Ensuring triage, early recognition, and source control (isolating patients with suspected COVID-19)
2. Applying standard precautions for all patients
3. Implementing empiric additional precautions (droplet and contact and, whenever applicable, airborne precautions) for suspected cases of COVID-19
4. Implementing administrative controls
5. Using environmental and engineering controls

# Ensuring triage, Early Recognition, and Source Control

- Encourage HCWs to have a high level of clinical suspicion
- Establish a well-equipped triage station at the entrance to the facility, supported by trained staff
- Institute the use of screening questionnaires according to the updated case definition; refer to the Global Surveillance for human infection with coronavirus disease (COVID-19) for case definitions
- Post signs in public areas reminding symptomatic patients to alert HCWs

# Applying Standard Precautions for all Patients

- Ensure that all patients cover their nose and mouth with a tissue or elbow when coughing or sneezing
- Offer a medical mask to patients with suspected COVID-19 while they are in waiting/public areas or in cohorting rooms
- Perform hand hygiene after contact with respiratory secretions
- Hand hygiene includes either cleansing hands with an alcohol-based hand rub or with soap and water
- Alcohol-based hand rubs are preferred if hands are not visibly soiled
- Wash hands with soap and water when they are visibly soiled

# Implementing Empiric Additional Precautions

- Contact and droplet precautions
  - Gloves, gowns, medical masks, eye protection
  - Donning and doffing appropriately
  - Requires education for HCW populations
  - Single use or dedicated equipment
  - Limit visitors
  - Refrain touching face/mask/eyes
  - Disinfect high touch surfaces
- Airborne precautions for aerosol-generating procedures
  - Well ventilated room
  - Use a particulate respirator at level of a NIOSH-certified N95 or (EU) standard FFP2, or equivalent

## Putting on (Donning) Personal Protective Equipment (PPE)

### 1 HAND HYGIENE



- A Using an alcohol-based hand rub is the preferred way to **clean your hands**.
- B If your hands look or feel dirty, soap and water must be used to wash your hands.

### 2 Gown



- A Make sure the gown covers from neck to knees to wrist.
- B Tie at the back of neck and waist.

### 3a Procedure/Surgical mask

- Secure the ties or elastic around your head so the mask stays in place.
- Fit the moldable band to the nose bridge. Fit snugly to your face and below chin.




### 3b N95 respirator

There are different styles of N95 respirators (pictured below). They include: a) molded cup, b) duckbill, c) flat-fold and d) v-fold



All styles have the same basic steps for donning; molded cup and duckbill are pictured below. Refer to the manufacturer for specific donning instructions.



- A Pre-stretch both top and bottom straps before placing the respirator on your face.
- B Cup the N95 respirator in your hand.
- C Position the N95 respirator under your chin with the nose piece up. Secure the elastic band around your head so the N95 respirator stays in place.
- D Use both hands to mold the metal band of the N95 respirator around the bridge of your nose.
- E Fit check the N95 respirator.

### 4 Eye protection or face shields



- Place over the eyes (or face).
- Adjust to fit.

### 5 Gloves




- Pull the cuffs of the gloves over the cuffs of the gown.



May 2014

## Taking off (Doffing) Personal Protective Equipment (PPE)

### 1 Gloves




- A Grasp the outside edge of the glove near the wrist and peel away from the hand, turning the glove inside-out.
- Hold the glove in the opposite gloved hand.
- B Slide an ungloved finger or thumb under the wrist of the remaining glove.
- C Peel the glove off and over the first glove, making a bag for both gloves.
- Put the gloves in the garbage.

### 2 HAND HYGIENE



- A Using an alcohol-based hand rub is the preferred way to **clean your hands**.
- B If your hands look or feel dirty, soap and water must be used to wash your hands.

### 3 Gown



- A Carefully unfasten ties.
- B Grasp the outside of the gown at the back of the shoulders and pull the gown down over the arms.
- C Turn the gown inside out during removal.
- Put in hamper or, if disposable, put in garbage.

### 4 HAND HYGIENE



- Clean your hands. (See No. 2)
- Exit the patient room, close the door and **clean your hands** again.

### 5 Eye protection or face shield



- Handle only by headband or ear pieces.
- Carefully pull away from face.
- Put reusable items in appropriate area for cleaning.
- Put disposable items into garbage.

### 6 Mask or N95 respirator



- Bend forward slightly and carefully remove the mask from your face by touching only the ties or elastic bands.
  - Start with the bottom tie, then remove the top tie.
  - Throw the mask in the garbage.
- There are different styles of N95 respirators but all styles have the same basic steps for doffing.

### 7 HAND HYGIENE

- Clean your hands. (See No. 2)

May 2014

# Administrative Measures related to Health Care Workers

- Provision of adequate training for HCWs
- Ensuring an adequate patient-to-staff ratio
- Establishing a surveillance process for acute respiratory infections potentially caused by COVID-19 virus among HCWs
- Ensuring that HCWs and the public understand the
- Importance of promptly seeking medical care
- Monitoring HCW compliance with standard precautions and providing mechanisms for improvement



# Using Environmental and Engineering Controls

- Address basic infrastructure of the health care facility<sup>14</sup> and aim to ensure adequate ventilation
- Maintain adequate environmental cleaning
- Separation of at least 1 metre between all patients
- Ensure that cleaning and disinfection procedures are followed consistently and correctly
- Manage laundry, food service utensils and medical waste in accordance with safe routine procedures



# References

- World Health Organization
  - <http://covid19.who.int>
- Questions ?